A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 [dalcetrapib] mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL [high-density lipoprotein] Levels
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Dalcetrapib (Primary) ; Simvastatin
- Indications Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Akros Pharma
- 23 Jun 2008 New trial record.